This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $30.84, moving +0.62% from the previous trading session.
Charles River (CRL) Offers Access to Preclinical Cancer Research
by Zacks Equity Research
Charles River (CRL) contributes to 84 percent of the FDA-approved cancer medicines and provides partners with 16 oncology prospects.
Pharma Stock Roundup: JNJ Posts Upbeat Q3 Earnings, PFE, NVO Revise 2023 View
by Kinjel Shah
J&J (JNJ) reports strong third-quarter results. Merck's (MRK) new deal with Japan's Daiichi Sankyo to jointly develop the latter's three DXd ADC candidates.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Pfizer (PFE) concluded the recent trading session at $32.75, signifying a -1.56% move from its prior day's close.
Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View
by Zacks Equity Research
Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.
Nu Holdings and Tyson Foods have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Nu Holdings and Tyson Foods have been highlighted as Zacks Bull and Bear of the Day.
Johnson & Johnson (JNJ) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 5.56% and 1.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Markets Pop on Bargain Hunting, Stronger Economy
by Mark Vickery
The small-cap Russell 2000, still under water over the past month, led the way higher today.
Pfizer's (PFE) Ulcerative Colitis Pill Etrasimod Gets FDA Nod
by Zacks Equity Research
The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.
Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls
by Zacks Equity Research
Pfizer (PFE) lowers its total revenue guidance for 2023 by $9 billion as sales from its COVID products, Comirnaty vaccine and Paxlovid pill decline.
The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics
by Zacks Equity Research
Pfizer, Allogene Therapeutics and Corcept Therapeutics are included in this Analyst Blog.
FDA Approves Pfizer's (PFE) Braftovi + Mektovi for Lung Cancer
by Zacks Equity Research
Pfizer's (PFE) Braftovi + Mektovi drug combo gets label expansion for BRAF V600E-mutant non-small cell lung cancer.
Pharma Stock Roundup: LLY Meets IBD Study Goal, PFE, MRK Give Cancer Pipeline Updates
by Kinjel Shah
Eli Lilly's (LLY) mirikizumab meets the main goals in a Crohn's disease study. PFE, MRK and JNJ provide updates on cancer drugs in their pipeline.
ETFs to Benefit From the Historic Exxon-Pioneer Oil Merger
by Sweta Killa
The largest U.S. oil producer, Exxon Mobil Corp. (XOM) has agreed to acquire Pioneer Natural Resources (PXD) in an all-stock deal valued at $59.5 billion or $253 per share.
The Zacks Analyst Blog UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer
by Zacks Equity Research
UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer are part of the Zacks Analyst Blog.
Top Analyst Reports for UnitedHealth, Chevron & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX) and AstraZeneca PLC (AZN).
Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data
by Zacks Equity Research
Ventyx Biosciences (VTYX) announces positive top-line data from a phase II study evaluating its pipeline candidate, VTX002, for treating moderate-to-severely active ulcerative colitis. Stock down.
The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer
by Zacks Equity Research
Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer are part of the Zacks top Analyst Blog.
Novavax (NVAX) Focuses on Diversifying Vaccines Portfolio
by Zacks Equity Research
Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indications.
Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus
by Kinjel Shah
The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.
BEAM Focuses on Developing Gene Drug for Growth
by Zacks Equity Research
While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.